Medicare Enrolled
Dr. Miguel Pelayo, M.D.
Medical Oncology · Bradenton, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Pelayo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pelayo? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pelayo
Dr. Miguel Pelayo is a medical oncology in Bradenton, FL, with 18 years in practice. Based on federal Medicare data, Dr. Pelayo performed 378,492 Medicare services across 7,204 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pelayo received a total of $5,765 from 64 pharmaceutical and/or device companies across 273 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pelayo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice▲ Top 3% volume in FL$ $5,765 industry payments
Medicare Practice Summary
Medicare Utilization ↗378,492
Medicare services
Top 3% in FL for medical oncology
7,204
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~21,027 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 199,920 | $0 | $4 |
| Iron sucrose injection (Venofer) | 24,300 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 22,400 | $43 | $137 |
| Anti-nausea injection (aprepitant) | 20,930 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 15,286 | $0 | $12 |
| Denosumab injection (Prolia/Xgeva) | 13,440 | $18 | $51 |
| Daratumumab injection (Darzalex) | 10,260 | $38 | $110 |
| Epoetin alfa injection (Procrit) for anemia | 10,150 | $6 | $23 |
| Epoetin alfa injection (Retacrit) for anemia | 7,190 | $6 | $22 |
| Immune globulin infusion (Gammagard) | 6,076 | $36 | $108 |
| Paclitaxel chemotherapy injection | 5,756 | $0 | $2 |
| Iron infusion (Monoferric) | 4,900 | $17 | $57 |
| Injection, eflapegrastim-xnst, 0.1 mg | 4,752 | $26 | $116 |
| Complete blood count (CBC) with differential | 4,097 | $8 | $29 |
| Blood draw (venipuncture) | 3,839 | $8 | $9 |
| Dexamethasone injection (steroid) | 3,408 | $0 | $3 |
| Contrast dye for imaging (iodine-based) | 2,660 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,050 | $1 | $28 |
| Office visit, established patient (20-29 min) | 1,549 | $65 | $239 |
| Drug injection, under skin or into muscle | 1,517 | $10 | $69 |
| Anti-nausea injection (ondansetron/Zofran) | 1,320 | $0 | $9 |
| Office visit, established patient (30-39 min) | 1,279 | $96 | $339 |
| Injection, leucovorin calcium, per 50 mg | 1,252 | $3 | $12 |
| Injection, atropine sulfate, 0.01 mg | 1,120 | $0 | $1 |
| Injection of additional new drug or substance into vein | 1,095 | $12 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 862 | $47 | $189 |
| Injection, fluorouracil, 500 mg | 841 | $2 | $7 |
| Administration of chemotherapy into vein, 1 hour or less | 793 | $97 | $378 |
| Injection, irinotecan, 20 mg | 683 | $2 | $177 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 669 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 355 | $15 | $56 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 329 | $3 | $205 |
| Injection, zoledronic acid, 1 mg | 293 | $7 | $69 |
| Injection, carboplatin, 50 mg | 242 | $2 | $41 |
| Administration of chemotherapy into vein, each additional hour | 230 | $21 | $79 |
| Injection, diphenhydramine hcl, up to 50 mg | 194 | $1 | $3 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 187 | $16 | $59 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 183 | $25 | $89 |
| Prothrombin time test (blood clotting) | 140 | $4 | $15 |
| Infusion into a vein for hydration, each additional hour | 139 | $10 | $42 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 139 | $54 | $206 |
| Administration of additional new drug or substance into vein, 1 hour or less | 136 | $49 | $178 |
| New patient office visit (30-44 min) | 129 | $83 | $298 |
| Injection of drug or substance into vein | 126 | $28 | $156 |
| Infusion, normal saline solution , 1000 cc | 122 | $2 | $7 |
| Administration of additional new drug or substance into vein using push technique | 116 | $42 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 113 | $135 | $562 |
| Red blood count automated, with additional calculations | 111 | $5 | $20 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 104 | $122 | $637 |
| Office visit, established patient, complex (40-54 min) | 94 | $134 | $474 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 87 | $15 | $56 |
| Automated urinalysis | 86 | $2 | $8 |
| New patient office visit (45-59 min) | 67 | $113 | $453 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $21 | $84 |
| Drawing of blood for a medical problem | 51 | $68 | $277 |
| Infusion into a vein for hydration, 31-60 minutes | 48 | $24 | $156 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 46 | $4 | $15 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 43 | $3 | $11 |
| Ct scan of chest with contrast | 31 | $53 | $351 |
| Red blood count, automated test | 30 | $4 | $10 |
| CT scan of abdomen and pelvis with contrast | 26 | $176 | $563 |
| New patient office visit, complex (60-74 min) | 24 | $133 | $585 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 13 | $401 | $680 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 12 | $1,098 | $3,706 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.2% high complexity
40.6% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,765
Total received (2018-2024)
Avg $824/year across 7 years
Bottom 46% in FL for medical oncology
64
Companies
273
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,438 (94.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$327 (5.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$794
2023$1,247
2022$687
2021$160
2020$193
2019$517
2018$2,166
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$558
Myriad Genetic Laboratories, Inc.
$530
Janssen Biotech, Inc.
$467
Exelixis Inc.
$464
PFIZER INC.
$325
Novartis Pharmaceuticals Corporation
$270
GENZYME CORPORATION
$266
Celgene Corporation
$229
ABBVIE INC.
$221
Lilly USA, LLC
$187
Genentech USA, Inc.
$167
Taiho Oncology, Inc.
$151
AstraZeneca Pharmaceuticals LP
$146
Gilead Sciences, Inc.
$138
Galvanize Therapeutics, Inc
$124
Amgen Inc.
$115
Takeda Pharmaceuticals U.S.A., Inc.
$89
ARRAY BIOPHARMA INC
$79
Ipsen Biopharmaceuticals, Inc
$77
Heron Therapeutics, Inc.
$57
Merck Sharp & Dohme Corporation
$57
Regeneron Healthcare Solutions, Inc.
$53
Incyte Corporation
$47
Helsinn Therapeutics (U.S.), Inc.
$46
Bayer HealthCare Pharmaceuticals Inc.
$46
GlaxoSmithKline, LLC.
$38
TESARO, Inc.
$35
Octapharma USA, Inc.
$32
AbbVie, Inc.
$32
AbbVie Inc.
$32
EMD Serono, Inc.
$32
TerSera Therapeutics LLC
$31
Clovis Oncology, Inc.
$30
Merck Sharp & Dohme LLC
$30
Daiichi Sankyo Inc.
$29
Sysmex Inostics Inc
$29
Spectrum Pharmaceuticals Inc.
$28
Fennec Pharmaceuticals, Inc.
$27
Seagen Inc.
$25
G1 Therapeutics, Inc.
$25
GE HealthCare
$25
MENARINI SILICON BIOSYSTEMS, INC.
$24
Myovant Sciences Inc.
$24
Pharmacosmos Therapeutics Inc.
$22
SANOFI-AVENTIS U.S. LLC
$22
Puma Biotechnology, Inc.
$20
Shire North American Group Inc
$19
Janssen Pharmaceuticals, Inc
$19
Amneal Pharmaceuticals LLC
$18
CSL Behring
$18
Novocure Inc.
$18
Sumitomo Pharma America, Inc.
$18
Jazz Pharmaceuticals Inc.
$17
MEDIVATION FIELD SOLUTIONS LLC
$16
BeiGene USA, Inc.
$16
PORTOLA PHARMACEUTICALS, INC.
$16
AMAG Pharmaceuticals, Inc.
$16
Blueprint Medicines Corporation
$15
EKOS Corporation
$15
Astellas Pharma US Inc
$13
Boston Scientific Corporation
$12
INSYS Therapeutics Inc
$11
Rigel Pharmaceuticals, Inc.
$5
Veracyte, Inc.
$1
Top 3 companies account for 27.0% of total payments
Associated products mentioned in payments ›
AKYNZEO · ALIYA SYSTEM · ANDEXXA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · CEREZYME · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · EKOSONIC · ELIQUIS · EMPLICITI · ENJAYMO · EPKINLY · ERLEADA · Enhertu · Erleada · FERAHEME · FRUZAQLA · Folotyn · GAZYVA · Hizentra · IBRANCE · IMBRUVICA · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LEMTRADA · LIBTAYO · LORBRENA · LUMAKRAS · LUPRON DEPOT · LYNPARZA · Lonsurf · MEKINIST · MYRISK · NINLARO · NURTEC ODT · Nerlynx · Nplate · ONUREG · OPDIVO · ORGOVYX · Oncology · Onivyde · PADCEV · PROMACTA · Pedmark · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · RYTARY · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SPRYCEL · SUSTOL · SYNDROS · TASIGNA · TAXOTERE · TECENTRIQ · TUKYSA · Trodelvy · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Varithena Administration Pack · Venclexta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XARELTO · XTANDI · Xofigo · Xospata · ZEJULA · ZOLADEX · ZYKADIA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
13
Per 100K population
3.1
County median income
$75,792
Nearest hospital
LAKEWOOD RANCH MEDICAL CENTER
3.4 mi
3.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Pelayo is a mixed practice specialist, with above-average Medicare volume (top 3% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Pelayo experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Pelayo performed 199,920 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pelayo receive payments from pharmaceutical companies?
Yes. Dr. Pelayo received a total of $5,765 from 64 companies across 273 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pelayo's costs compare to other medical oncologys in Bradenton?
Dr. Pelayo's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pelayo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Bradenton
Browse medical oncologys in Bradenton ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology